April 17th 2025
These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.
Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease
January 27th 2016Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.
Read More
Smoking Can Reduce Survival of Breast Cancer Patients
January 27th 2016A study published in the Journal of Clinical Oncology has found that smoking before and after diagnosis of breast cancer is associated with increased mortality from breast cancer as well as other conditions, including respiratory and cardiovascular disease.
Read More
How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH
January 25th 2016An educational session on Patient-Reported Outcomes in Hematology at the annual meeting of the American Society of Hematology, discussed the importance of embracing the patient perspective in healthcare delivery.
Read More
Experts Share Concepts of Quality Measures and Pay-for-Performance With Hematologists
January 25th 2016At the annual meeting of the American Society of Hematology, experts discussed quality measurement, public performance reporting, and pay-for-performance and it's impact on healthcare in the United States.
Read More
This Week in Managed Care: January 23, 2016
January 23rd 2016Top managed care stories this week included UnitedHealth reporting larger-than-expected losses on Affordable Care Act health plans, new guidelines from the government that will improve patient access to medical records, and new information that can reduce risk of diabetes.
Watch
Dr Kavital Patel Examines Accounting for Drug Costs in Total Cost of Care
January 23rd 2016Kavita Patel, MD, fellow in economic studies and managing director at Brookings Institution, discussed how the cost of drugs should be accounted for in the total cost of care, and the importance of considering patient needs when offering drugs.
Watch
Abundant Optimism at the ASH/FDA Joint Symposium on New Drug Approvals in Multiple Myeloma
January 21st 2016At a joint session at the annual meeting of the American Society of Hematology, primary clinical reviewers from the FDA discussed the safety and efficacy issues of 3 very recently approved drugs for multiple myeloma, along with 2 clinicians who have extensive experience with these drugs in the real-world setting.
Read More
New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting
January 21st 2016A session on the first day of the annual meeting of the American Society of Hematology, held December 5-8, 2015, in Orlando, Florida, clinicians discussed the promise and challenges of using newly approved hematology/oncology agents.
Read More
Study Narrows Time to Surgery Following Chemoradiotherapy in Rectal Cancer
January 20th 2016A retrospective analysis of data from the National Cancer Data Base has found that patients who had cancer surgery at 56 days after the end of combined chemoradiotherapy presented with the best overall survival and successful removal of their residual tumors.
Read More
This Week in Managed Care: January 16, 2016
January 16th 2016This week in managed care the top stories included the announcement of a initiative to cure cancer, pharmaceutical company executives brushed off public outrage over drug prices, and the president's nominee for FDA commissioner has passed his first hurdle.
Read More
Dr Patrick Soon-Shiong's Dream Team: The National Immunotherapy Coalition
January 14th 2016The National Immunotherapy Coalition has coalesced leaders from large pharma, biotech, academic cancer centers, community oncologists, and a health plan, with the hope of accelerating the development path of next generation immunotherapy in oncology.
Read More